Title |
Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
|
---|---|
Published in |
EJNMMI Research, October 2016
|
DOI | 10.1186/s13550-016-0233-4 |
Pubmed ID | |
Authors |
Christina Bluemel, Fraenze Linke, Ken Herrmann, Iva Simunovic, Matthias Eiber, Christian Kestler, Andreas K. Buck, Andreas Schirbel, Thorsten A. Bley, Hans-Juergen Wester, Daniel Vergho, Axel Becker |
Abstract |
Salvage radiotherapy (SRT) is clinically established in prostate cancer (PC) patients with PSA persistence or biochemical relapse (BCR) after prior radical surgery. PET/CT imaging prior to SRT may be performed to localize disease recurrence. The recently introduced (68)Ga-PSMA outperforms other PET tracers for detection of recurrence and is therefore expected also to impact radiation planning. Forty-five patients with PSA persistence (16 pts) or BCR (29 pts) after prior prostatectomy, scheduled to undergo SRT of the prostate bed, underwent (68)Ga-PSMA PET/CT. The median PSA level was 0.67 ng/ml. The impact of (68)Ga-PSMA PET/CT on the treatment decision was assessed. Patients with oligometastatic (≤5 lesions) PC underwent radiotherapy (RT), with the extent of the RT area and dose escalation being based on PET positivity. Suspicious lesions were detected in 24/45 (53.3 %) patients. In 62.5 % of patients, lesions were only detected by (68)Ga-PSMA PET. Treatment was changed in 19/45 (42.2 %) patients, e.g., extending SRT to metastases (9/19), administering dose escalation in patients with morphological local recurrence (6/19), or replacing SRT by systemic therapy (2/19). 38/45 (84.4 %) followed the treatment recommendation, with data on clinical follow-up being available in 21 patients treated with SRT. All but one showed biochemical response (mean PSA decline 78 ± 19 %) within a mean follow-up of 8.12 ± 5.23 months. (68)Ga-PSMA PET/CT impacts treatment planning in more than 40 % of patients scheduled to undergo SRT. Future prospective studies are needed to confirm this significant therapeutic impact on patients prior to SRT. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 74 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 17 | 23% |
Student > Master | 11 | 15% |
Student > Postgraduate | 6 | 8% |
Other | 6 | 8% |
Student > Bachelor | 5 | 7% |
Other | 14 | 19% |
Unknown | 15 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 40 | 54% |
Immunology and Microbiology | 3 | 4% |
Nursing and Health Professions | 2 | 3% |
Agricultural and Biological Sciences | 2 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 1% |
Other | 7 | 9% |
Unknown | 19 | 26% |